Skip to main content

Pulzium

Generic name: tedisamil
Treatment for: Atrial Flutter, Atrial Fibrillation

Solvay Pharmaceuticals Files Tedisamil, a New CardiometabolicProduct for the Treatment of Atrial Fibrillation and Atrial Flutter

BRUSSELS, Belguim, April 25, 2007--Solvay announced today that its dossier for intravenous tedisamil (intended brand name: Pulzium IV), a new chemical entity coming from Solvay Pharmaceuticals R&D laboratories, has been filed for approval by the US Food and Drug Administration (FDA) as well as by the authorities of European Union countries. This means that the formal processing and review have begun.

The regulatory submission is based on safety and efficacy studies that evaluated Pulzium IV for the rapid conversion of recent onset atrial fibrillation or atrial flutter to normal sinus rhythm in more than 1000 patients with symptomatic atrial fibrillation or flutter. Pulzium IV is a class III anti-arrhythmic drug which blocks multiple potassium channels.

“We believe that Pulzium IV represents a valuable treatment option for cardiologists treating patients with recent onset atrial fibrillation or flutter. Used as a 30 minute intravenous infusion, it converts atrial flutter or fibrillation back to sinus rhythm and becomes a worthwhile addition to the other cardiometabolic treatments we offer”, said Claus Steinborn, Executive Vice President R&D of Solvay Pharmaceuticals.

Solvay Pharmaceuticals is a research driven group of companies that constitute the global pharmaceutical business of the Solvay Group. The company seeks to fulfill carefully selected, unmet medical needs in the therapeutic areas of cardio-metabolic, neuroscience, influenza vaccines, gastroenterology, specialized markets and men’s and women’s health. Its 2006 sales were EUR 2.6 billion and it employs approximately 10,000 people worldwide.
SOLVAY is an international chemical and pharmaceutical Group with headquarters in Brussels. It employs some 29,000 people in 50 countries. In 2006, its consolidated sales amounted to EUR 9.4 billion, generated by its three sectors of activity: Chemicals, Plastics and Pharmaceuticals. Solvay (Euronext: SOLB.BE - Bloomberg: SOLB.BB - Reuters: SOLBt.BR) is listed on the Euronext stock exchange in Brussels. For further information please contact :

Roger Bickerstaffe , VP Communications
Solvay Pharmaceuticals
Tel: +31 (0) 294 477 242
Fax: +31 (0) 294 477 112
E-mail : roger.bickerstaffe@solvay.com

Robert van Bijlert ,
SOLVAY PHARMACEUTICALS B.V
Tel: +31 (0) 294 479 577
Fax: +31 (0) 294 477 112
E-mail : robert.vanbijlert@solvay.com

Martial Tardy , Corporate Press Officer
SOLVAY SA Headquarters
Tel: 32 2 509 72 30
Fax: 32 2 509 72 40
E-mail : martial.tardy@solvay.com

Patrick Verelst , Investor Relations
SOLVAY SA
Tel: 32 2 509 72 43
Fax: 32 2 509 72 40
E-mail : patrick.verelst@solvay.com

Posted: April 2007

Related articles

Pulzium (tedisamil) FDA Approval History

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.